Guidelines for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum

Ka Hee Yi; Kyung Won Kim; Chang Hoon Yim; Eui Dal Jung; Jin-Hoon Chung; Hyun-Kyung Chung; Soon Cheol Hong; Jae Hoon Chung

doi:10.11106/jkta.2014.7.1.7

Journal List > J Korean Thyroid Assoc > v.7(1) > 1056570

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Hee Yi, Won Kim, Hoon Yim, Dal Jung, Chung, Chung, Cheol Hong, and Hoon Chung: Guidelines for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum

Special Contribution

J Korean Thyroid Assoc 2014;7(1):7-39.

Published online: 29 May 2014

DOI: https://doi.org/10.11106/jkta.2014.7.1.7

Guidelines for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum

Ka Hee Yi¹, Kyung Won Kim², Chang Hoon Yim³, Eui Dal Jung⁴, Jin-Hoon Chung⁵, Hyun-Kyung Chung⁶, Soon Cheol Hong⁷, Jae Hoon Chung⁸

¹Department of Internal Medicine, Seoul National University College of Medicine, Boramae Medical Center, Seoul, Korea

²Seoul, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea

³Seoul, Department of Internal Medicine, Seoul, Korea

⁴Cheil General Hospital & Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Department of Internal Medicine, School of Medicine, Catholic University of Daegu, Seoul, Korea

⁵Obstetrics and Gynecology, Seoul, Korea

⁶Daegu, Department of Internal Medicine, Dankook University College of Medicine, Seoul, Korea

⁷Cheonan, Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea

⁸Seoul, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Ka Hee Yi, MD, PhD, Department of Internal Medicine, Seoul National University College of Medicine, Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, Korea Tel: 82-2-870-3203, Fax: 82-2-870-3866, E-mail: khyi@snu.ac.kr

Received 29 December 2021 Accepted 29 December 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R. et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011; 21(10):1081–125.

2. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D. et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007; 92(8 Suppl):S1–47.

3. Gharib H, Cobin RH, Dickey RA. Subclinical hypothyroidism during pregnancy: position statement from the American Association of Clinical Endocrinologists. Endocr Pract. 1999; 5:367–8.

4. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997; 18(3):404–33.

5. van Raaij JM, Vermaat-Miedema SH, Schonk CM, Peek ME, Hautvast JG. Energy requirements of pregnancy in The Netherlands. Lancet. 1987; 2(8565):953–5.

6. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF. et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003; 13(1):3–126.

7. Negro R. Significance and management of low TSH in pregnancy. In:. Lazarus J, Pirags V, Butz S. editors. The thyroid and reproduction. New York: Georg Thieme Verlag. 2009; p.84–95.

8. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid. 2004; 14(12):1084–90.

9. Kahric-Janicic N, Soldin SJ, Soldin OP, West T, Gu J, Jonklaas J. Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid. 2007; 17(4):303–11.

10. Soldin OP, Hilakivi-Clarke L, Weiderpass E, Soldin SJ. Trimester-specific reference intervals for thyroxine and triiodothyronine in pregnancy in iodine-sufficient women using isotope dilution tandem mass spectrometry and immunoassays. Clin Chim Acta. 2004; 349(1-2):181–181.

11. Sapin R, D’Herbomez M, Schlienger JL. Free thyroxine measured with equilibrium dialysis and nine immunoassays decreases in late pregnancy. Clin Lab. 2004; 50(9-10):581–581.

12. Roti E, Gardini E, Minelli R, Bianconi L, Flisi M. Thyroid function evaluation by different commercially available free thyroid hormone measurement kits in term pregnant women and their newborns. J Endocrinol Invest. 1991; 14(1):1–9.

13. Stricker R, Echenard M, Eberhart R, Chevailler MC, Perez V, Quinn FA. et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol. 2007; 157(4):509–14.

14. Soldin OP, Soldin D, Sastoque M. Gestation-specific thyroxine and thyroid stimulating hormone levels in the United States and worldwide. Ther Drug Monit. 2007; 29(5):553–9.

15. Panesar NS, Li CY, Rogers MS. Reference intervals for thyroid hormones in pregnant Chinese women. Ann Clin Biochem. 2001; 38(Pt 4):329–32.

16. Marwaha RK, Chopra S, Gopalakrishnan S, Sharma B, Kanwar RS, Sastry A. et al. Establishment of reference range for thyroid hormones in normal pregnant Indian women. BJOG;2008; 115(5):602–6.

17. Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ. The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. J Med Screen. 2004; 11(4):170–4.

18. Bocos-Terraz JP, Izquierdo-Alvarez S, Bancalero-Flores JL, Alvarez-Lahuerta R, Aznar-Sauca A, Real-Lopez E. et al. Thyroid hormones according to gestational age in pregnant Spanish women. BMC Res Notes. 2009; 2:237.

19. Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, Leveno KJ. et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol. 2005; 106(4):753–7.

20. Walker JA, Illions EH, Huddleston JF, Smallridge RC. Racial comparisons of thyroid function and autoimmunity during pregnancy and the postpartum period. Obstet Gynecol. 2005; 106(6):1365–71.

21. Price A, Obel O, Cresswell J, Catch I, Rutter S, Barik S. et al. Comparison of thyroid function in pregnant and nonpregnant Asian and western Caucasian women. Clin Chim Acta. 2001; 308(1-2):91–91.

22. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, van der Wal MF, Bonsel GJ. Ethnic differences in TSH but not in free T4 concentrations or TPO antibodies during pregnancy. Clin Endocrinol (Oxf). 2007; 66(6):765–70.

23. Thienpont LM, Van Uytfanghe K, Beastall G, Faix JD, Ieiri T, Miller WG. et al. Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clin Chem. 2010; 56(6):902–11.

24. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol. 2006; 107(2 Pt 1):337–41.

25. Toft AD, Backett GJ. Measuring serum thyrotropin and thyroid hormone and assessing thyroid hormone transport. In : Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: a fundamental and clinical text. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins;2005; p.329–44.

26. Anckaert E, Poppe K, Van Uytfanghe K, Schiettecatte J, Foulon W, Thienpont LM. FT4 immunoassays may display a pattern during pregnancy similar to the equilibrium dialysis ID-LC/tandem MS candidate reference measurement procedure in spite of susceptibility towards binding protein alterations. Clin Chim Acta. 2010; 411(17-18):1348–1348.

27. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE. et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol. 2009; 200(3):260–e1-6.

28. Stockigt J. Assessment of thyroid function: towards an integrated laboratory–clinical approach. Clin Biochem Rev. 2003; 24(4):109–22.

29. Thienpont LM, Van Uytfanghe K, Beastall G, Faix JD, Ieiri T, Miller WG. et al. Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 2: free thyroxine and free triiodothyronine. Clin Chem. 2010; 56(6):912–20.

30. Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ. et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen. 2000; 7(3):127–30.

31. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ. et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105(2):239–45.

32. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J. et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999; 341(8):549–55.

33. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid. 2002; 12(1):63–8.

34. Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993; 81(3):349–53.

35. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab. 2010; 95(4):1699–707.

36. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab. 2010; 95(9):E44–8.

37. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol. 2009; 160(6):985–91.

38. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF. et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008; 112(1):85–92.

39. Mannisto T, Vaarasmaki M, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM. et al. Thyroid dysfunction and autoantibodies during pregnancy as predictive factors of pregnancy complications and maternal morbidity in later life. J Clin Endocrinol Metab. 2010; 95(3):1084–94.

40. Mannisto T, Vaarasmaki M, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM. et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. J Clin Endocrinol Metab. 2009; 94(3):772–9.

41. Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. Thyroid. 2010; 20(9):989–93.

42. Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: psychoneurological deficits of progeny. Ann Clin Lab Sci. 1991; 21(4):227–39.

43. Man EB, Jones WS, Holden RH, Mellits ED. Thyroid function in human pregnancy. 8. Retardation of progeny aged 7 years; relationships to maternal age and maternal thyroid function. Am J Obstet Gynecol. 1971; 111(7):905–16.

44. Lazarus JH, Bestwick JP, Channon S, Paradice R, Maina A, Rees R. et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012; 366(6):493–501.

45. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clin Endocrinol (Oxf). 2003; 59(3):282–8.

46. Li Y, Shan Z, Teng W, Yu X, Li Y, Fan C. et al. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months. Clin Endocrinol (Oxf). 2010; 72(6):825–9.

47. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ. et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. J Clin Endocrinol Metab. 2010; 95(9):4227–34.

48. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004; 351(3):241–9.

49. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990; 323(2):91–6.

50. Kaplan MM. Monitoring thyroxine treatment during pregnancy. Thyroid. 1992; 2(2):147–52.

51. Loh JA, Wartofsky L, Jonklaas J, Burman KD. The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 2009; 19(3):269–75.

52. Yassa L, Marqusee E, Fawcett R, Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010; 95(7):3234–41.

53. Abalovich M, Alcaraz G, Kleiman-Rubinsztein J, Pavlove MM, Cornelio C, Levalle O. et al. The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism. Thyroid. 2010; 20(10):1175–8.

54. Galofre JC, Haber RS, Mitchell AA, Pessah R, Davies TF. Increased postpartum thyroxine replacement in Hashimoto's thyroiditis. Thyroid. 2010; 20(8):901–8.

55. Glinoer D, Riahi M, Grun JP, Kinthaert J. Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. J Clin Endocrinol Metab. 1994; 79(1):197–204.

56. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab. 2006; 91(7):2587–91.

57. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003; 148(4):389–93.

58. Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002; 87(4):1687–91.

59. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE. et al. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid. 2007; 17(7):609–12.

60. Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R. et al. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid. 2008; 18(1):7–12.

61. Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007; 92(4):1263–8.

62. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF. et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 147(4):217–23.

63. Braverman LE, Utiger RD. Introduction to thyrotoxicosis. In : Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: a fundamental and clinical tex. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins;2005; p.453–5.

64. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010; 31(5):702–55.

65. Patil-Sisodia K, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract. 2010; 16(1):118–29.

66. Goodwin TM, Montoro M, Mestman JH. Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects. Am J Obstet Gynecol. 1992; 167(3):648–52.

67. Tan JY, Loh KC, Yeo GS, Chee YC. Transient hyperthyroidism of hyperemesis gravidarum. BJOG;2002; 109(6):683–8.

68. Niebyl JR. Clinical practice. Nausea and vomiting in pregnancy. N Engl J Med. 2010; 363(16):1544–50.

69. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update. 2005; 11(5):527–39.

70. Grun JP, Meuris S, De Nayer P, Glinoer D. The thyrotrophic role of human chorionic gonadotrophin (hCG) in the early stages of twin (versus single) pregnancies. Clin Endocrinol (Oxf). 1997; 46(6):719–25.

71. Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid. 1999; 9(7):653–7.

72. Rodien P, Bremont C, Sanson ML, Parma J, Van Sande J, Costagliola S. et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med. 1998; 339(25):1823–6.

73. Glinoer D, Spencer CA. Serum TSH determinations in pregnancy: how, when and why? Nat Rev Endocrinol. 2010; 6(9):526–9.

74. Bouillon R, Naesens M, Van Assche FA, De Keyser L, De Moor P, Renaer M. et al. Thyroid function in patients with hyperemesis gravidarum. Am J Obstet Gynecol. 1982; 143(8):922–6.

75. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol. 2009; 160(1):1–8.

76. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol. 1989; 160(1):63–70.

77. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol. 1994; 84(6):946–9.

78. Papendieck P, Chiesa A, Prieto L, Gruneiro-Papendieck L. Thyroid disorders of neonates born to mothers with Graves’ disease. J Pediatr Endocrinol Metab. 2009; 22(6):547–53.

79. Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, Vannasaeng S, Nitiyanant W, Boonnamsiri V. et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf). 2001; 54(3):365–70.

80. Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol. 2004; 190(1):211–7.

81. Azizi F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 2006; 5(1):107–16.

82. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab. 2001; 86(6):2354–9.

83. Barbero P, Valdez R, Rodriguez H, Tiscornia C, Mansilla E, Allons A. et al. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet A. 2008; 146A(18):2390–5.

84. Clementi M, Di Gianantonio E, Cassina M, Leoncini E, Botto LD, Mastroiacovo P. et al. Treatment of hyperthyroidism in pregnancy and birth defects. J Clin Endocrinol Metab. 2010; 95(11):E337–41.

85. Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet. 1999; 83(1):43–6.

86. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL. et al. The Role of Propylthiouracil in the Management of Graves’ Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009; 19(7):673–4.

87. Rivkees SA, Mattison DR. Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol. 2009; 2009:132041.

88. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004; 10(8):1018–23.

89. Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med. 1981; 305(22):1323–6.

90. Sherif IH, Oyan WT, Bosairi S, Carrascal SM. Treatment of hyperthyroidism in pregnancy. Acta Obstet Gynecol Scand. 1991; 70(6):461–3.

91. Mestman JH, Manning PR, Hodgman J. Hyperthyroidism and pregnancy. Arch Intern Med. 1974; 134(3):434–9.

92. Glinoer D. Thyroid hyperfunction during pregnancy. Thyroid. 1998; 8(9):859–64.

93. Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Antithyroid drug therapy for Graves’ disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med. 1986; 315(1):24–8.

94. Ochoa-Maya MR, Frates MC, Lee-Parritz A, Seely EW. Resolution of fetal goiter after discontinuation of propylthiouracil in a pregnant woman with Graves’ hyperthyroidism. Thyroid. 1999; 9(11):1111–4.

95. Hamburger JI. Diagnosis and management of Graves’ disease in pregnancy. Thyroid. 1992; 2(3):219–24.

96. Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K. et al. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves’ disease. J Clin Endocrinol Metab. 1982; 55(1):108–12.

97. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol. 1998; 139(6):584–6.

98. Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K. Effects of iodine on thyroid status of fetus versus mother in treatment of Graves’ disease complicated by pregnancy. J Clin Endocrinol Metab. 1992; 75(3):738–44.

99. Kempers MJ, van Trjn DA, van Trotsenburg AS, de Vijlder JJ, Wiedijk BM, Vulsma T. Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J Clin Endocrinol Metab. 2003; 88(12):5851–7.

100. Zwaveling-Soonawala N, van Trotsenburg P, Vulsma T. Central hypothyroidism in an infant born to an adequately treated mother with Graves’ disease: an effect of maternally derived thyrotrophin receptor antibodies? Thyroid. 2009; 19(6):661–2.

101. Gruner C, Kollert A, Wildt L, Dorr HG, Beinder E, Lang N. Intrauterine treatment of fetal goitrous hypothyroidism controlled by determination of thyroid-stimulating hormone in fetal serum. A case report and review of the literature. Fetal Diagn Ther. 2001; 16(1):47–51.

102. Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M. et al. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab. 2005; 90(11):6093–8.

103. McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992; 2(2):155–9.

104. Mitsuda N, Tamaki H, Amino N, Hosono T, Miyai K, Tanizawa O. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol. 1992; 80(3 Pt 1):359–64.

105. Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis. Obstet Gynecol. 2002; 99(6):1040–3.

106. Zimmerman D. Fetal and neonatal hyperthyroidism. Thyroid. 1999; 9(7):727–33.

107. Cohen O, Pinhas-Hamiel O, Sivan E, Dolitski M, Lipitz S, Achiron R. Serial in utero ultrasonographic measurements of the fetal thyroid: a new complementary tool in the management of maternal hyperthyroidism in pregnancy. Prenat Diagn. 2003; 23(9):740–2.

108. Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME. et al. Fetal and neonatal thyroid function in relation to maternal Graves’ disease. Best Pract Res Clin Endocrinol Metab. 2004; 18(2):289–302.

109. Huel C, Guibourdenche J, Vuillard E, Ouahba J, Piketty M, Oury JF. et al. Use of ultrasound to distinguish between fetal hyperthyroidism and hypothyroidism on discovery of a goiter. Ultrasound Obstet Gynecol. 2009; 33(4):412–20.

110. Porreco RP, Bloch CA. Fetal blood sampling in the management of intrauterine thyrotoxicosis. Obstet Gynecol. 1990; 76(3 Pt 2):509–12.

111. Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: a study of 606 consecutive cases. Am J Obstet Gynecol. 1985; 153(6):655–60.

112. Kilpatrick S. Umbilical blood sampling in women with thyroid disease in pregnancy: Is it necessary? Am J Obstet Gynecol. 2003; 189(1):1–2.

113. Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab. 2004; 18(2):303–16.

114. Azizi F. Treatment of post-partum thyrotoxicosis. J Endocrinol Invest. 2006; 29(3):244–7.

115. Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R. et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008; 93(10):3985–8.

116. Benhaim Rochester D, Davies TF. Increased risk of Graves’ disease after pregnancy. Thyroid. 2005; 15(11):1287–90.

117. Rotondi M, Pirali B, Lodigiani S, Bray S, Leporati P, Chytiris S. et al. The post partum period and the onset of Graves’ disease: an overestimated risk factor. Eur J Endocrinol. 2008; 159(2):161–5.

118. Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J Endocrinol Invest. 2002; 25(6):493–6.

119. Azizi F, Bahrainian M, Khamseh ME, Khoshniat M. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol Metab. 2003; 16(9):1239–43.

120. Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE. et al. Incidence of early loss of pregnancy. N Engl J Med. 1988; 319(4):189–94.

121. Ellish NJ, Saboda K, O’Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod. 1996; 11(2):406–12.

122. Toth B, Jeschke U, Rogenhofer N, Scholz C, Wurfel W, Thaler CJ. et al. Recurrent miscarriage: current concepts in diagnosis and treatment. J Reprod Immunol. 2010; 85(1):25–32.

123. Dudley DJ. Diabetic-associated stillbirth: incidence, pathophysiology, and prevention. Clin Perinatol. 2007; 34(4):611–26. vii.

124. De Vivo A, Mancuso A, Giacobbe A, Moleti M, Maggio Savasta L, De Dominici R. et al. Thyroid function in women found to have early pregnancy loss. Thyroid. 2010; 20(6):633–7.

125. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez-Marfany M, Davies TF. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA. 1990; 264(11):1422–5.

126. Iijima T, Tada H, Hidaka Y, Mitsuda N, Murata Y, Amino N. Effects of autoantibodies on the course of pregnancy and fetal growth. Obstet Gynecol. 1997; 90(3):364–9.

127. Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M. et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991; 73(2):421–7.

128. Sezer K, Kamel N, Unlu C, Celik HK. Impact of first trimester and postpartum period thyroid autoantibodies on abortus incidence in Turkish pregnant women. Gynecol Endocrinol. 2009; 25(6):387–91.

129. Prummel MF, Wiersinga WM. Thyroid autoimmunity and miscarriage. Eur J Endocrinol. 2004; 150(6):751–5.

130. Imaizumi M, Pritsker A, Kita M, Ahmad L, Unger P, Davies T. Pregnancy and murine thyroiditis: thyroglobulin immunization leads to fetal loss in specific allogeneic pregnancies. Endocrinology. 2001; 142(2):823–9.

131. Lee YL, Ng HP, Lau KS, Liu WM, O WS, Yeung WS. et al. Increased fetal abortion rate in autoimmune thyroid disease is related to circulating TPO autoantibodies in an autoimmune thyroiditis animal model. Fertil Steril. 2009; 91(5 Suppl):2104–9.

132. Matalon ST, Blank M, Levy Y, Carp HJ, Arad A, Burek L. et al. The pathogenic role of anti-thyroglobulin antibody on pregnancy: evidence from an active immunization model in mice. Hum Reprod. 2003; 18(5):1094–9.

133. Lee RM, Silver RM. Recurrent pregnancy loss: summary and clinical recommendations. Semin Reprod Med. 2000; 18(4):433–40.

134. Baek KH, Lee EJ, Kim YS. Recurrent pregnancy loss: the key potential mechanisms. Trends Mol Med. 2007; 13(7):310–7.

135. Iravani AT, Saeedi MM, Pakravesh J, Hamidi S, Abbasi M. Thyroid autoimmunity and recurrent spontaneous abortion in Iran: a case-control study. Endocr Pract. 2008; 14(4):458–64.

136. Kutteh WH, Yetman DL, Carr AC, Beck LA, Scott RT Jr. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertil Steril. 1999; 71(5):843–8.

137. Esplin MS, Branch DW, Silver R, Stagnaro-Green A. Thyroid autoantibodies are not associated with recurrent pregnancy loss. Am J Obstet Gynecol. 1998; 179(6 Pt 1):1583–6.

138. Pratt DE, Kaberlein G, Dudkiewicz A, Karande V, Gleicher N. The association of antithyroid antibodies in euthyroid nonpregnant women with recurrent first trimester abortions in the next pregnancy. Fertil Steril. 1993; 60(6):1001–5.

139. Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod. 2000; 15(7):1637–9.

140. De Carolis C, Greco E, Guarino MD, Perricone C, Dal Lago A, Giacomelli R. et al. Anti-thyroid antibodies and antiphospholipid syndrome: evidence of reduced fecundity and of poor pregnancy outcome in recurrent spontaneous aborters. Am J Reprod Immunol. 2004; 52(4):263–6.

141. Kiprov DD, Nachtigall RD, Weaver RC, Jacobson A, Main EK, Garovoy MR. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Am J Reprod Immunol. 1996; 36(4):228–34.

142. Stricker RB, Steinleitner A, Bookoff CN, Weckstein LN, Winger EE. Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. Fertil Steril. 2000; 73(3):536–40.

143. Vaquero E, Lazzarin N, De Carolis C, Valensise H, Moretti C, Ramanini C. Mild thyroid abnormalities and recurrent spontaneous abortion: diagnostic and therapeutical approach. Am J Reprod Immunol. 2000; 43(4):204–8.

144. Bussen S, Steck T, Dietl J. Increased prevalence of thyroid antibodies in euthyroid women with a history of recurrent in-vitro fertilization failure. Hum Reprod. 2000; 15(3):545–8.

145. Kim CH, Chae HD, Kang BM, Chang YS. Influence of antithyroid antibodies in euthyroid women on in vitro fertilization-embryo transfer outcome. Am J Reprod Immunol. 1998; 40(1):2–8.

146. Poppe K, Glinoer D, Tournaye H, Devroey P, van Steirteghem A, Kaufman L. et al. Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J Clin Endocrinol Metab. 2003; 88(9):4149–52.

147. Kilic S, Tasdemir N, Yilmaz N, Yuksel B, Gul A, Batioglu S. The effect of anti-thyroid antibodies on endometrial volume, embryo grade and IVF outcome. Gynecol Endocrinol. 2008; 24(11):649–55.

148. Negro R, Formoso G, Coppola L, Presicce G, Mangieri T, Pezzarossa A. et al. Euthyroid women with autoimmune disease undergoing assisted reproduction technologies: the role of autoimmunity and thyroid function. J Endocrinol Invest. 2007; 30(1):3–8.

149. Toulis KA, Goulis DG, Venetis CA, Kolibianakis EM, Negro R, Tarlatzis BC. et al. Risk of spontaneous miscarriage in euthyroid women with thyroid autoimmunity undergoing IVF: a meta-analysis. Eur J Endocrinol. 2010; 162(4):643–52.

150. Negro R, Mangieri T, Coppola L, Presicce G, Casavola EC, Gismondi R. et al. Levothyroxine treatment in thyroid peroxidase antibody-positive women undergoing assisted reproduction technologies: a prospective study. Hum Reprod. 2005; 20(6):1529–33.

151. Martin JA, Osterman MJ, Sutton PD. Are preterm births on the decline in the United States? Recent data from the National Vital Statistics System. NCHS Data Brief. 2010; (39):1–8.

152. Mathews TJ, Menacker F, MacDorman MF. Centers for Disease Control and Prevention, National Center for Health Statistics. Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep. 2004; 53(10):1–29.

153. Petrou S. The economic consequences of preterm birth during the first 10 years of life. BJOG;2005; 112(Suppl 1):10–5.

154. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008; 371(9606):75–84.

155. Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: a cohort study. Arch Gynecol Obstet. 2011; 283(2):243–7.

156. Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am. 1995; 79(1):169–84.

157. Ghafoor F, Mansoor M, Malik T, Malik MS, Khan AU, Edwards R. et al. Role of thyroid peroxidase antibodies in the outcome of pregnancy. J Coll Physicians Surg Pak. 2006; 16(7):468–71.

158. Haddow JE, Cleary-Goldman J, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G. et al. Thyroperoxidase and thyroglobulin antibodies in early pregnancy and preterm delivery. Obstet Gynecol. 2010; 116(1):58–62.

159. Struve CW, Haupt S, Ohlen S. Influence of frequency of previous pregnancies on the prevalence of thyroid nodules in women without clinical evidence of thyroid disease. Thyroid. 1993; 3(1):7–9.

160. Kung AW, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002; 87(3):1010–4.

161. Tan GH, Gharib H, Goellner JR, van Heerden JA, Bahn RS. Management of thyroid nodules in pregnancy. Arch Intern Med. 1996; 156(20):2317–20.

162. Rosen IB, Walfish PG, Nikore V. Pregnancy and surgical thyroid disease. Surgery. 1985; 98(6):1135–40.

163. Marley EF, Oertel YC. Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol. 1997; 16(2):122–5.

164. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003; 189(4):1128–35.

165. Loh KC. Familial nonmedullary thyroid carcinoma: a metareview of case series. Thyroid. 1997; 7(1):107–13.

166. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med. 2004; 351(17):1764–71.

167. Tucker MA, Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M. et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991; 51(11):2885–8.

168. Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med. 1995; 155(22):2418–23.

169. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME. et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006; 12(1):63–102.

170. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS. et al. Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer. J Korean Thyroid Assoc. 2010; 3(2):65–96.

171. Brander A, Viikinkoski P, Tuuhea J, Voutilainen L, Kivisaari L. Clinical versus ultrasound examination of the thyroid gland in common clinical practice. J Clin Ultrasound. 1992; 20(1):37–42.

172. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F. et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002; 87(5):1941–6.

173. Bennedbaek FN, Hegedus L. Management of the solitary thyroid nodule: results of a North American survey. J Clin Endocrinol Metab. 2000; 85(7):2493–8.

174. Bennedbaek FN, Perrild H, Hegedus L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf). 1999; 50(3):357–63.

175. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003; 24(1):102–32.

176. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S. et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007; 92(2):450–5.

177. Atkinson BF. Fine needle aspiration of the thyroid. Monogr Pathol. 1993; (35):166–99.

178. Belfiore A, La Rosa GL. Fine-needle aspiration biopsy of the thyroid. Endocrinol Metab Clin North Am. 2001; 30(2):361–400.

179. Choe W, McDougall IR. Thyroid cancer in pregnant women: diagnostic and therapeutic management. Thyroid. 1994; 4(4):433–5.

180. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987; 31(5):587–90.

181. Hamburger JI. Thyroid nodules in pregnancy. Thyroid. 1992; 2(2):165–8.

182. Oertel YC. Fine-needle aspiration and the diagnosis of thyroid cancer. Endocrinol Metab Clin North Am. 1996; 25(1):69–91.

183. Powers C, Frable W. Fine needle aspiration biopsy of the head and neck. Boston, MA: Butterworth-Heinemann;1996.

184. Singer PA. Evaluation and management of the solitary thyroid nodule. Otolaryngol Clin North Am. 1996; 29(4):577–91.

185. Solomon D. Fine needle aspiration of the thyroid: an update. Thyroid Today. 1993; 16:1–9.

186. Zanzonico PB. Radiation dose to patients and relatives incident to 131I therapy. Thyroid. 1997; 7(2):199–204.

187. Pauwels EK, Thomson WH, Blokland JA, Schmidt ME, Bourguignon M, El-Maghraby TA. et al. Aspects of fetal thyroid dose following iodine-131 administration during early stages of pregnancy in patients suffering from benign thyroid disorders. Eur J Nucl Med. 1999; 26(11):1453–7.

188. Berg GE, Nystrom EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S. et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998; 39(2):357–61.

189. Herzon FS, Morris DM, Segal MN, Rauch G, Parnell T. Coexistent thyroid cancer and pregnancy. Arch Otolaryngol Head Neck Surg. 1994; 120(11):1191–3.

190. Monroy-Lozano BE, Hurtado-Lopez LM, Zaldivar-Ramirez FR, Basurto-Kuba E. Clinical behavior of thyroid papillary cancer in pregnancy: optimal time for its treatment. Ginecol Obstet Mex. 2001; 69:359–62.

191. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997; 82(9):2862–6.

192. Nam KH, Yoon JH, Chang HS, Park CS. Optimal timing of surgery in well-differentiated thyroid carcinoma detected during pregnancy. J Surg Oncol. 2005; 91(3):199–203.

193. Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D. et al. Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol. 2010; 162(1):145–51.

194. Vini L, Hyer S, Pratt B, Harmer C. Good prognosis in thyroid cancer found incidentally at surgery for thyrotoxicosis. Postgrad Med J. 1999; 75(881):169–70.

195. Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B. et al. Thyroid cancer in pregnancy. Int J Gynaecol Obstet. 2005; 91(1):15–20.

196. Rosen IB, Walfish PG. Pregnancy as a predisposing factor in thyroid neoplasia. Arch Surg. 1986; 121(11):1287–90.

197. Chong KM, Tsai YL, Chuang J, Hwang JL, Chen KT. Thyroid cancer in pregnancy: a report of 3 cases. J Reprod Med. 2007; 52(5):416–8.

198. Doherty CM, Shindo ML, Rice DH, Montero M, Mestman JH. Management of thyroid nodules during pregnancy. Laryngoscope. 1995; 105(3 Pt 1):251–5.

199. Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg. 2009; 144(5):399–406. discussion.

200. Mestman JH, Goodwin TM, Montoro MM. Thyroid disorders of pregnancy. Endocrinol Metab Clin North Am. 1995; 24(1):41–71.

201. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167–214.

202. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154(6):787–803.

203. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD. et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008; 69(3):479–90.

204. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbe M, Ceccarelli C. et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med. 2008; 49(5):845–52.

205. Rosvoll RV, Winship T. Thyroid carcinoma and pregnancy. Surg Gynecol Obstet. 1965; 121(5):1039–42.

206. Hill CS Jr, Clark RL, Wolf M. The effect of subsequent pregnancy on patients with thyroid carcinoma. Surg Gynecol Obstet. 1966; 122(6):1219–22.

207. Leboeuf R, Emerick LE, Martorella AJ, Tuttle RM. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid. 2007; 17(6):543–7.

208. Rosario PW, Barroso AL, Purisch S. The effect of subsequent pregnancy on patients with thyroid carcinoma apparently free of the disease. Thyroid. 2007; 17(11):1175–6.

209. Hirsch D, Levy S, Tsvetov G, Weinstein R, Lifshitz A, Singer J. et al. Impact of pregnancy on outcome and prognosis of survivors of papillary thyroid cancer. Thyroid. 2010; 20(10):1179–85.

210. Amino N, Mori H, Iwatani Y, Tanizawa O, Kawashima M, Tsuge I. et al. High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med. 1982; 306(14):849–52.

211. Stagnaro-Green A. Clinical review 152: Postpartum thyroiditis. J Clin Endocrinol Metab. 2002; 87(9):4042–7.

212. Stagnaro-Green A, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Negro R. High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab. 2011; 96(3):652–7.

213. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Wallenstein S, Davies TF. A prospective study of lymphocyteinitiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab. 1992; 74(3):645–53.

214. Muller AF, Drexhage HA, Berghout A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: recent insights and consequences for antenatal and postnatal care. Endocr Rev. 2001; 22(5):605–30.

215. Kuijpens JL, De Hann-Meulman M, Vader HL, Pop VJ, Wiersinga WM, Drexhage HA. Cell-mediated immunity and postpartum thyroid dysfunction: a possibility for the prediction of disease? J Clin Endocrinol Metab. 1998; 83(6):1959–66.

216. Smallridge RC. Postpartum thyroid disease: a model of immunologic dysfunction. Clin Appl Immunol Rev. 2000; 1:89–103.

217. Adams H, Jones MC, Othman S, Lazarus JH, Parkes AB, Hall R. et al. The sonographic appearances in postpartum thyroiditis. Clin Radiol. 1992; 45(5):311–5.

218. Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid. 2006; 16(6):573–82.

219. Alvarez-Marfany M, Roman SH, Drexler AJ, Robertson C, Stagnaro-Green A. Long-term prospective study of postpartum thyroid dysfunction in women with insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1994; 79(1):10–6.

220. Gerstein HC. Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. Ann Intern Med. 1993; 118(6):419–23.

221. Elefsiniotis IS, Vezali E, Pantazis KD, Saroglou G. Post-partum thyroiditis in women with chronic viral hepatitis. J Clin Virol. 2008; 41(4):318–9.

222. Stagnaro-Green A, Akhter E, Yim C, Davies TF, Magder L, Petri M. Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery. Lupus. 2011; 20(7):690–9.

223. Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves’ disease. Thyroid. 2007; 17(8):767–72.

224. Lazarus JH, Ammari F, Oretti R, Parkes AB, Richards CJ, Harris B. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract. 1997; 47(418):305–8.

225. Caixas A, Albareda M, Garcia-Patterson A, Rodriguez-Espinosa J, de Leiva A, Corcoy R. Postpartum thyroiditis in women with hypothyroidism antedating pregnancy? J Clin Endocrinol Metab. 1999; 84(11):4000–5.

226. Walfish PG, Meyerson J, Provias JP, Vargas MT, Papsin FR. Prevalence and characteristics of post-partum thyroid dysfunction: results of a survey from Toronto, Canada. J Endocrinol Invest. 1992; 15(4):265–72.

227. Lazarus JH. Clinical manifestations of postpartum thyroid disease. Thyroid. 1999; 9(7):685–9.

228. Hayslip CC, Fein HG, O’Donnell VM, Friedman DS, Klein TA, Smallridge RC. The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction. Am J Obstet Gynecol. 1988; 159(1):203–9.

229. Cox JL, Murray D, Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry. 1993; 163:27–31.

230. Pop VJ, de Rooy HA, Vader HL, van der Heide D, van Son M, Komproe IH. et al. Postpartum thyroid dysfunction and depression in an unselected population. N Engl J Med. 1991; 324(25):1815–6.

231. Lucas A, Pizarro E, Granada ML, Salinas I, Sanmarti A. Postpartum thyroid dysfunction and postpartum depression: are they two linked disorders? Clin Endocrinol (Oxf). 2001; 55(6):809–14.

232. Kuijpens JL, Vader HL, Drexhage HA, Wiersinga WM, van Son MJ, Pop VJ. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. Eur J Endocrinol. 2001; 145(5):579–84.

233. Harris B, Othman S, Davies JA, Weppner GJ, Richards CJ, Newcombe RG. et al. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ;1992; 305(6846):152–6.

234. Pop VJ, de Rooy HA, Vader HL, van der Heide D, van Son MM, Komproe IH. Microsomal antibodies during gestation in relation to postpartum thyroid dysfunction and depression. Acta Endocrinol (Copenh). 1993; 129(1):26–30.

235. Harris B, Oretti R, Lazarus J, Parkes A, John R, Richards C. et al. Randomised trial of thyroxine to prevent postnatal depression in thyroid-antibody-positive women. Br J Psychiatry. 2002; 180:327–30.

236. Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, Amino N. Prediction of post-partum Graves’ thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. Clin Endocrinol (Oxf). 1994; 41(1):15–20.

237. Azizi F. The occurrence of permanent thyroid failure in patients with subclinical postpartum thyroiditis. Eur J Endocrinol. 2005; 153(3):367–71.

238. Fung HY, Kologlu M, Collison K, John R, Richards CJ, Hall R. et al. Postpartum thyroid dysfunction in Mid Glamorgan. Br Med J (Clin Res Ed). 1988; 296(6617):241–4.

239. Vargas MT, Briones-Urbina R, Gladman D, Papsin FR, Walfish PG. Antithyroid microsomal autoantibodies and HLA-DR5 are associated with postpartum thyroid dysfunction: evidence supporting an autoimmune pathogenesis. J Clin Endocrinol Metab. 1988; 67(2):327–33.

240. Tachi J, Amino N, Tamaki H, Aozasa M, Iwatani Y, Miyai K. Long term follow-up and HLA association in patients with postpartum hypothyroidism. J Clin Endocrinol Metab. 1988; 66(3):480–4.

241. Rasmussen NG, Hornnes PJ, Hoier-Madsen M, Feldt-Rasmussen U, Hegedus L. Thyroid size and function in healthy pregnant women with thyroid autoantibodies. Relation to development of postpartum thyroiditis. Acta Endocrinol (Copenh). 1990; 123(4):395–401.

242. Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab. 2012; 97(2):334–42.

243. Nohr SB, Jorgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? J Clin Endocrinol Metab. 2000; 85(9):3191–8.

244. Kampe O, Jansson R, Karlsson FA. Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis. J Clin Endocrinol Metab. 1990; 70(4):1014–8.

245. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A. et al. Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf). 1991; 35(1):41–6.

246. Dosiou C, Sanders GD, Araki SS, Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol. 2008; 158(6):841–51.

247. Thung SF, Funai EF, Grobman WA. The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. Am J Obstet Gynecol. 2009; 200(3):267–e1-7.

248. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S. et al. Detection of thyroid dysfunction in early pregnancy: Universal screening or targeted high-risk case finding? J Clin Endocrinol Metab. 2007; 92(1):203–7.

249. Horacek J, Spitalnikova S, Dlabalova B, Malirova E, Vizda J, Svilias I. et al. Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. Eur J Endocrinol. 2010; 163(4):645–50.

250. De Carlucci D Jr, Tavares MR, Obara MT, Martins LA, Hojaij FC, Cernea CR. Thyroid function after unilateral total lobectomy: risk factors for postoperative hypothyroidism. Arch Otolaryngol Head Neck Surg. 2008; 134(10):1076–9.

251. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4):526–34.

252. Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with biochemical disease? J Gen Intern Med. 1997; 12(9):544–50.

253. Jovanovic-Peterson L, Peterson CM. De novo clinical hypothyroidism in pregnancies complicated by type I diabetes, subclinical hypothyroidism, and proteinuria: a new syndrome. Am J Obstet Gynecol. 1988; 159(2):442–6.

254. Ladenson PW. Diagnosis of hypothyroidism. In : Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: a fundamental and clinical text. 9th ed. Philadelphia, PA: Lippincott, Williams & Wilkins;2005; p.857–63.

255. Poppe K, Glinoer D, Van Steirteghem A, Tournaye H, Devroey P, Schiettecatte J. et al. Thyroid dysfunction and autoimmunity in infertile women. Thyroid. 2002; 12(11):997–1001.

256. Mercado G, Adelstein DJ, Saxton JP, Secic M, Larto MA, Lavertu P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer. 2001; 92(11):2892–7.

257. Rotondi M, Leporati P, La Manna A, Pirali B, Mondello T, Fonte R. et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol. 2009; 160(3):403–8.

258. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG. et al. Thyroid function in humans with morbid obesity. Thyroid. 2006; 16(1):73–8.

259. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2):489–99.

260. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23(6):735–51.

261. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23(6):723–33.

262. Vagenakis AG, Braverman LE. Adverse effects of iodides on thyroid function. Med Clin North Am. 1975; 59(5):1075–88.

Fig. 1.

An algorithm for the work-up and treatment of a thyroid nodule detected during pregnancy.

Fig. 2.

An algorithm for the treatment and monitoring of postpartum thyroiditis.

Fig. 3.

An algorithm for the interpretation and management of the results of first trimester screening. TFT: thyroid function test.

Table 1.

Grade definition according to the United States Preventive Services Task Force (USPSTF) Guidelines

Strength of recommendations	Grade definition
Level A	The USPSTF strongly recommends that clinicians provide (the service) to eligible patients. The USPSTF found good evidence that (the service) improves important health outcomes and concludes that benefits substantially outweigh harms.
Level B	The USPSTF recommends that clinicians provide (this service) to eligible patients. The USPSTF found at least fair evidence that (the service) improves important health outcomes and concludes that benefits outweigh harms.
Level C	The USPSTF makes no recommendation for or against routine provision of (the service). The USPSTF found at least fair evidence that (the service) can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.
Level D	The USPSTF recommends against routinely providing (the service) to asymptomatic patients. The USPSTF found at least fair evidence that (the service) is ineffective or that harms outweigh benefits.
Level I	The USPSTF concludes that evidence is insufficient to recommend for or against routinely providing (the service). Evidence that (the service) is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.

TOOLS

Similar articles